Estrogen treatment is preventive and curative for the breast cancer even in BRCA mutation carriers
What is it about?
Despite currently available concept, BRCA mutation is an imbalanced defect, crudely inhibiting the upregulation of estrogen receptor (ER) expression and liganded transcriptional activity, whereas ER-repressor functions become predominant. Compensatory high estrogen synthesis may upregulate the interplay between ERs and defective BRCA protein and restores the DNA repairing processes. BRCA-mutation carrier women may apparently be healthy or exhibit clinical signs of deficient estrogen signaling in spite of hyperestrogenism.
Why is it important?
In BRCA-mutation carriers, defective estrogen signaling is associated with decreased genome stability and induces tumor development with conspicuous specificity for female organs having cyclic proliferative activity, such as the breast, endometrium and ovary.
The following have contributed to this page: professor Zsuzsanna Suba
In partnership with: